These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16061711)

  • 1. Phosphodiesterase type 5 and high altitude pulmonary hypertension.
    Aldashev AA; Kojonazarov BK; Amatov TA; Sooronbaev TM; Mirrakhimov MM; Morrell NW; Wharton J; Wilkins MR
    Thorax; 2005 Aug; 60(8):683-7. PubMed ID: 16061711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
    Ghofrani HA; Voswinckel R; Reichenberger F; Olschewski H; Haredza P; Karadaş B; Schermuly RT; Weissmann N; Seeger W; Grimminger F
    J Am Coll Cardiol; 2004 Oct; 44(7):1488-96. PubMed ID: 15464333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.
    Michelakis ED; Tymchak W; Noga M; Webster L; Wu XC; Lien D; Wang SH; Modry D; Archer SL
    Circulation; 2003 Oct; 108(17):2066-9. PubMed ID: 14568893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil citrate therapy for pulmonary arterial hypertension.
    Galiè N; Ghofrani HA; Torbicki A; Barst RJ; Rubin LJ; Badesch D; Fleming T; Parpia T; Burgess G; Branzi A; Grimminger F; Kurzyna M; Simonneau G;
    N Engl J Med; 2005 Nov; 353(20):2148-57. PubMed ID: 16291984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
    Wharton J; Strange JW; Møller GM; Growcott EJ; Ren X; Franklyn AP; Phillips SC; Wilkins MR
    Am J Respir Crit Care Med; 2005 Jul; 172(1):105-13. PubMed ID: 15817798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
    Steiner MK; Preston IR; Klinger JR; Hill NS
    Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy.
    Rondelet B; Kerbaul F; Van Beneden R; Motte S; Fesler P; Hubloue I; Remmelink M; Brimioulle S; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2004 Oct; 110(15):2220-5. PubMed ID: 15466636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension.
    Singh TP; Rohit M; Grover A; Malhotra S; Vijayvergiya R
    Am Heart J; 2006 Apr; 151(4):851.e1-5. PubMed ID: 16569546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure.
    Guazzi M; Tumminello G; Di Marco F; Fiorentini C; Guazzi MD
    J Am Coll Cardiol; 2004 Dec; 44(12):2339-48. PubMed ID: 15607396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.
    Klein A; Zils U; Bopp C; Gries A; Martin E; Gust R
    J Surg Res; 2007 Apr; 138(2):224-30. PubMed ID: 17275845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?
    Chapman TH; Wilde M; Sheth A; Madden BP
    Vascul Pharmacol; 2009; 51(2-3):90-5. PubMed ID: 19386283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
    Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
    Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
    Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
    J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure.
    Stehlik J; Movsesian MA
    J Card Fail; 2009 Feb; 15(1):31-4. PubMed ID: 19181291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease.
    Madden BP; Allenby M; Loke TK; Sheth A
    Vascul Pharmacol; 2006 May; 44(5):372-6. PubMed ID: 16574495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.